Bristol-Myers Squibb Guides FY23 Adj. EPS In Line; Q4 Results Top Estimates

RTTNews | Před 740 dny
Stocktwits
Bristol-Myers Squibb Guides FY23 Adj. EPS In Line; Q4 Results Top Estimates

(RTTNews) - While reporting financial results for the fourth quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) provided earnings, adjusted earnings and revenue guidance for the full-year 2023.

For fiscal 2023, the company now projects earnings in a range of $4.03 to $4.33 per share and adjusted earnings of $7.95 to $8.25 per share on worldwide total revenue growth of about 2 percent.

On average, 21 analysts polled by Thomson Reuters expect the company to report earnings of $8.0 per share on revenues growth of 2.7 percent to $47.15 billion for the year. Analysts' estimates typically exclude special items.

For the fourth quarter, the company reported net income attributable to Bristol-Myers Squibb of $2.02 billion or $0.95 per share, down from $2.37 billion or $1.07 per share in the prior-year quarter. Excluding items, adjusted net earnings per share for the quarter was $1.82, compared to last year's $1.84.

Total revenues for the quarter declined 5 percent to $11.41 billion from $11.99 billion in the same quarter last year.

Analysts expected quarterly earnings of $1.72 per share on revenues of $11.20 billion for the quarter.

U.S. revenues increased 5 percent to $7.9 billion, while international revenues decreased 22 percent to $3.5 billion from last year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Značky : BMY
Stocktwits
read more
Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation

Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation

Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
RTTNews | Před 281 dny
Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers

Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers

Radiopharmaceutical company Perspective Therapeutics, Inc. (CATX) announced Tuesday a clinical trial collaboration agreement with Bristol Myers Squibb Co. (BMY) to evaluate the safety and tolerability of Perspective's targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb's nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans.
RTTNews | Před 329 dny
Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal

Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal

Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announced Tuesday a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
RTTNews | Před 413 dny
Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash

Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash

Bristol-Myers Squibb Co. (BMY) and biopharmaceutical company Karuna Therapeutics, Inc. (KRTX) announced Friday that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
RTTNews | Před 417 dny
Nástroje
Ekonomický kalendář
Market Hours
Interest Rates
Holidays Calendar
Forexový trh
Forex volatilita
Korelace Forexu
Novinky na Forexu
forex analysis
COT údaje
Likvidita
Forex kalkulačky
Forex Tepelná mapa
Indicators Heatmap
Komunita
Komunita
Systémy
Nejpopulárnější systémy
Strategie
Soutěže
Forexové grafy
Forexový sentiment
Indikátor Outlook
Recenze
Brokeři
Prop Trading Firms
Služby VPS
Poskytovatelé signálu
Služby programování EA
Affiliate Programs
Služby PAMM Brokera
Služby slevového programu
Obchodní platformy
Odborní poradci
Kryptoburzy
Trading Courses
Brokeři
Forex Spready
Nabídky Forex brokerů
Swapy Forex brokerů
Objem brokera Forexu
Propagační akce Forex Brokera Broker News
Platforma
Miniaplikace
Funkce
API
RSS
Stock Portfolio
Affiliate Software
Rozšířené grafy
Podpora
Faq
Pomoc
Kontaktuj nás
Nahlásit chybu!
O
Blog
& copy; 2025 Myfxbook Ltd. Všechna práva vyhrazena.
UPOZORNĚNÍ NA VYSOKÉ RIZIKO: Obchodování s devizami přináší vysokou úroveň rizika, které nemusí být vhodné pro všechny investory. Páka vytváří další rizika a ztráty. Než se rozhodnete obchodovat s devizami, důkladně zvažte své investiční cíle, úroveň zkušeností a toleranci vůči riziku. Můžete přijít o část nebo všechny své počáteční investice. Neinvestujte peníze, které si nemůžete dovolit ztratit. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všechny údaje a informace jsou poskytovány "tak, jak jsou". pouze pro informační účely a nejsou určeny pro obchodní účely nebo rady. Výkonnost v minulosti neznamená výkonnost v budoucnosti.